Targeting Pathogenic Myelopoiesis in Pancreatic Cancer

Official record

Identifier

NCT07765316

Recruiting locations

Locations are not included in the offline baseline for this record. Open the official record to see the current site list.

Interventions studied

Not provided in the official record

Lead sponsor

IRCCS San Raffaele

Target enrolment

100 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Not yet recruiting

First posted

Aug 14, 2026

Last updated on the registry

Aug 17, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria

* For all participants:
* Age ≥18 years.
* Ability and willingness to autonomously provide written informed consent.
* For the PDAC cohort:
* Clinical diagnosis of non-metastatic pancreatic ductal adenocarcinoma (PDAC).
* Treatment-naïve status at the time of blood collection, with no prior chemotherapy, radiotherapy, or immunotherapy for PDAC.
* Newly diagnosed non-metastatic pancreatic cancer eligible for multimodal treatment.
* Candidate for standard clinical management at IRCCS Ospedale San Raffaele.
* For the age-matched control cohort:
* Patient followed at the Pancreatic Cystic Lesion outpatient clinic of IRCCS Ospedale San Raffaele.
* Diagnosis of intraductal papillary mucinous neoplasm (IPMN) under surveillance, with no evidence of pancreatic malignancy at the time of enrollment.
* Age within ±5 years of the corresponding PDAC cohort to allow age-matched comparator analyses.
* Exclusion Criteria
* For all participants:
* Inability to autonomously provide informed consent.
* For the PDAC cohort:
* Failure to meet the inclusion criteria for the PDAC cohort.
* Presence of severe comorbidities that, in the investigator's opinion, may interfere with study participation or interpretation of study results.
* Previous systemic anti-cancer treatment for PDAC.
* Use of anti-inflammatory drugs, including NSAIDs or immunomodulators.
* Events or conditions affecting inflammatory parameters, including acute inflammatory or infectious events such as cholangitis, jaundice, or recent invasive procedures.
* Hematologic diseases.
* Clinically significant hematological abnormalities that may interfere with immune profiling analyses, as assessed by the investigator.
* For the age-matched control cohort:
* Any acute or chronic inflammatory condition or ongoing infection.
* Any history of cancer or immunological disorders.

Indexed under

Pancreatic Cancer